Search / 13 results found

from
to
  • Updated

AUBURN, Wash., Aug. 6, 2021 /PRNewswire/ -- A new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center revealed for the first time that activation of CXCR2 may be a general resistance-response to non-small cell lung cancer (NSCLC) treatments that inhibit the RAS/RAF/MEK/ERK signaling pathway, and may explain why many patients with lung cancer do not respond to such treatments.

  • Updated

Laura Guadalupe Aguiar Garibay, beloved wife, daughter, sister, and friend to many, passed away with her family by her side close to 6:00 a.m. on June 9, 2021, following a courageous battle with cancer.

  • Updated

SEATTLE, June 15, 2021 /PRNewswire/ -- Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing. The proceeds will enable Umoja to continue development of its integrated technologies, advance its product candidates based on CAR T-cell adapter-mediated tumor-targeting (TumorTag) and the in vivo modification of immune cells (VivoVec and RACR/CAR) into clinical development, and build internal manufacturing capabilities to support preclinical and clinical development of its pipeline programs.

  • Updated

SEATTLE, June 7, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Thierry Guillaudeux, Ph.D., SVP Immuno-oncology at Kineta, will participate in the virtual symposium "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond," taking place on June 18, 2021.

When Peggy Rosales, 63, started experiencing trouble in her stomach, she had no idea the breath-taking pain was being caused by a rare form of disease.